Ty-jour t1 - 趋化因子的作用，他们的基因多态性在可重演NSCLC JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003.Congress-2020.4094 VL - 56 IS - Spect 64 SP - 4094 Au - Drösslerová，Marie Au- Šterclová，Martina Au - Vašáková，Martina Au - Tašková，Alice Au - Hytych，vladislav Au - Richterová，伊娃·奥地拉 - Matějčková，米拉达Y1 - 2020/09/07 UR - //www.qdcxjkg.com/content/56 / sprever_64 / 4094.Abstract n2 - 目标：趋化因子是针对肿瘤的免疫反应的一部分。趋化因子表达受基因多态性的影响。他们的角色在可重定型的NSCLC.aim中尚不清楚：将可重置的NSCLC患者的血浆中的趋化因素浓度（CCL2，CCL8，CXCL12）与没有癌症的人进行比较。要了解趋化因子浓度是否根据疾病的阶段而异。评估基因多态性CCL2 RS3760396，CCL8 RS3138035，CXCL12 RS1804429。为了了解基因多态性是否在NSCLC患者和没有癌症的那些之间的不同。他们经历了标准的诊断和分期过程。我们诊断出42例NSCLC患者，27名患者患有良性肺病理（对照组）。我们通过ELISA LSBIO套件评估了外周血中的趋化因子浓度。 We assessed gene polymorphisms by quantitative real- time polymerase chain reaction with TaqMan hydrolysis probes. Parametric statistics was used for analysis.Results: There was no difference in concentrations of chemokines in plasma of NSCLC patients and control group. The CXCL12 concentrations positively corelated with the tumor extent expressed by clinical stage (mean values: stage I 5.08ng/ml; SEM 0.59; stage II and IIIA 7.82ng/ml; SEM 1.06; p= 0.022). There was no difference in gene polymorphisms between NSCLC patients and control group (CCL2 rs3760396 p= 0.160; CCL8 rs3138035 p= 0.589; CXCL12 rs1804429 p= 0.233).Conclusion: The CXCL12 relates tumor growth and might be a biomarker of advanced disease. We might need to include more patients to find out more about gene polymorphisms.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 4094.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -